Buscar
01/02/2023
Outcome of COVID-19 infection in people with diabetes mellitus or obesity in the primary care setting in Catalonia, Spain: A retrospective cohort study of the initial three waves
Mauricio, D, Vlacho, B, Ortega, E, Cos-Claramunt, X, Mata-Cases, M, Real, J, Fernandez-Camins, B, Franch-Nadal, J. Outcome of COVID-19 infection in people with diabetes mellitus or obesity in the primary care setting in Catalonia, Spain: A retrospective cohort study of the initial three waves. Primary Care Diabetes. 2023; 17(1)DOI:10.1016/j.pcd.2022.12.002. PMID:36528549. IF:2.600(Q1/3D).
01/01/2023
All-cause and cardiorenal mortality in 6 million adults with and without type 2 diabetes: A comparative, trend analysis in Canada, Spain, and the UK
Ling S., Zaccardi F., Vlacho B., Li P., Gatius, JR, Mata-Cases M., Franch-Nadal J., Kosiborod M.N., Gillies C., Fenici P., Mauricio D., Shah B.R., Khunti K.. All-cause and cardiorenal mortality in 6 million adults with and without type 2 diabetes: A comparative, trend analysis in Canada, Spain, and the UK. DIABETES OBESITY & METABOLISM. 2023; 25(1)DOI:10.1111/dom.14856. PMID:36056765. IF:5.400(Q1/2D).
01/01/2023
Type 2 Diabetes mellitus alters the cargo of (poly)phenol metabolome and the oxidative status in circulating lipoproteins
Reis A., Rocha S., Dias I.H., Costa R., Soares R., Sánchez-Quesada J.L., Perez A., de Freitas V.. Type 2 Diabetes mellitus alters the cargo of (poly)phenol metabolome and the oxidative status in circulating lipoproteins. Redox Biology. 2023; 59DOI:10.1016/j.redox.2022.102572. PMID:36516720. IF:10.700(Q1/1D).
01/01/2023
Glycaemic Control in People with Type 2 Diabetes Mellitus Switching from Basal Insulin to Insulin Glargine 300 U/ml (Gla-300): Results from the REALI Pooled Database
Muller-Wieland, D, Freemantle, N, Bonadonna, RC, Mauquoi, C, Bigot, G, Bonnemaire, M, Gourdy, P, Mauricio, D. Glycaemic Control in People with Type 2 Diabetes Mellitus Switching from Basal Insulin to Insulin Glargine 300 U/ml (Gla-300): Results from the REALI Pooled Database. Diabetes Therapy. 2023; 14(2)DOI:10.1007/s13300-022-01356-3. PMID:36596946. IF:2.800(Q3/6D).